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Abstract 
Hyperpolarization of 13C-labeled substrates can increase their 13C NMR signal 
by more than 10,000-fold, which has allowed magnetic resonance imaging (MRI) of 
metabolic reactions in vivo. This has already provided a unique insight into the 
dysregulated metabolic pathways and microenvironment of tumors. Perhaps the best 
known of the cancer-associated metabolic abberations is the Warburg effect, which 
has been imaged in patients using hyperpolarized [1-13C]pyruvate. In clinical 
oncology there is a requirement to diagnose tumors earlier, better determine their 
aggressiveness and prognosis, identify novel treatment targets and detect response 
to treatment earlier. Here we consider some of the hyperpolarized substrates that 
have been developed and have the potential to meet these requirements and 
become the precision imaging tools of the future.  
 
Introduction 
 
For most cancers imaging is important for diagnosis, prognosis, guiding 
treatment and monitoring subsequent response.  Computed tomography (CT) and 
magnetic resonance imaging (MRI) give anatomical information, but provide limited 
information about tumor biology.  As personalized oncology becomes a reality, the 
development of functional imaging techniques is required to complement the range 
of emerging genetic and molecular tests.  
Warburg’s observation that tumor cells preferentially metabolize glucose to 
lactate in normoxia, rather than oxidize it in the TCA cycle, led him to falsely 
conclude that cancer was a metabolic disease caused by mitochondrial dysfunction 
[1].  Remarkably it took another 46 years for the first proto-oncogene, SRC, to be 
discovered, leading to the realization that cancer is a disease resulting from genetic 
mutation and instability [2]. We now know that some key metabolic pathways are 
under direct control of the most frequently mutated oncogenes and tumor suppressor 
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genes and, although the Warburg effect is a characteristic of many tumors, it is just 
one feature of the metabolic reprogramming that occurs and is required to support 
tumor growth [3,4]. 
Functional imaging techniques have been developed that non-invasively 
probe tissue biochemistry, many of which interrogate the dysregulated metabolic 
processes that are a hallmark of cancer [5]. A wide range of radiopharmaceuticals 
have been developed and employed clinically for use with positron emission 
tomography (PET) [6,7]. Whilst PET offers unrivalled sensitivity (in the femtomolar to 
picomolar range), the limitation is that the tracer and downstream metabolic products 
cannot be differentiated. Paradoxically, 1H or 13C magnetic resonance spectroscopy 
(MRS) are able to differentiate between metabolites but are limited by sensitivity [8]. 
 Dissolution dynamic nuclear polarization (DNP) of 13C labeled substrates can 
increase the signal-to-noise ratio in 13C magnetic resonance spectra and 
spectroscopic images by >104, permitting real-time spectroscopy or spectroscopic 
imaging of the injected substrate and its conversion to downstream metabolic 
products (Box 1).  Due to its position in the glycolytic pathway, favorable polarization 
levels and polarization lifetime, hyperpolarized [1-13C]pyruvate has been the most 
widely used substrate in pre-clinical studies and has also been used in clinical 
studies [9,10]. It is transported into cells by monocarboxylate transporters (MCTs) 
and in tumors is reduced predominantly to lactate, in the reaction catayzed by lactate 
dehydrogenase (LDH). [1-13C]alanine and 13C-bicarbonate are also detectable in 
smaller quantities following pyruvate transamination and decarboxylation, 
respectively [11-13].  Various hyperpolarized substrates have been used to study 
cancer metabolism (Table 1 and Fig. 1). There are several recent comprehensive 
reviews of hyperpolarized MRI [14-17]. We focus here on recent applications of 
hyperpolarized MRI in oncology, which in some cases have the potential for clinical 
translation. 
 
Box 1 
Dissolution Dynamic Nuclear Polarization (DNP)  
 Hyperpolarization can be achieved in a number of ways but DNP has been 
the most widely used.  Although it can in principle be used with any NMR-active 
nucleus the majority of studies have been performed with 13C-labeled molecules 
because of the relatively long polarization lifetime for this nucleus and the possibility 
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of measuring metabolic fluxes with 13C-labeled cell metabolites.  The 13C labeled 
substrate to be hyperpolarized is mixed with a stable radical and rapidly frozen to 
form a glass. At temperatures approaching 1 K, and in the presence of a strong 
magnetic field (> 3 Tesla), the electron spins on the radical are almost completely 
polarized. Excitation of the electron spin resonance by microwave irradiation results 
in transfer of the electron spin polarization to the nuclear spins.  The hyperpolarized 
13C-labeled metabolite is then brought rapidly to room temperature, with substantial 
retention of the nuclear spin polarization in a process that involves injection of a 
super-heated aqueous solvent (~450 K) [16,18]. After dissolution the polarization 
lasts from seconds to a few minutes, depending on the molecule and the position of 
the 13C nucleus within the molecule, with its half-life determined by the longitudinal 
relaxation time constant (T1). 
  
Screening, diagnosis and disease progression  
  
 Hyperpolarized imaging has already shown clinical diagnostic potential in a 
first-in-man study in prostate cancer [9]. An elevated [1-13C]lactate/[1-13C]pyruvate 
ratio was observed in tumor regions and in one patient a biopsy-proven tumor was 
identified by hyperpolarized imaging but not by multi-parametric 1H-MRI [9]. 
 In prostate cancer there is a requirement for new approaches to determine 
tumor aggressiveness. In men over sixty 30-70% are estimated to have prostate 
cancer but the vast majority require no treatment [19]. However, 30% of patients 
defined as being low-risk actually harbor higher-grade tumors that would benefit from 
early treatment [20]. As nearly 80% of cases present with localized disease [21], 
imaging with hyperpolarized [1-13C]pyruvate is a potentially useful tool for 
determining the aggressiveness of these tumors. In a recent study [1-13C]pyruvate 
was co-polarized with 13C-urea (an agent for imaging perfusion) and injected into a 
transgenic mouse model of prostate adenocarcinoma (TRAMP). Both agents 
differentiated high- and low-grade tumors, with high-grade tumors showing increased 
lactate labeling and reduced perfusion but higher vascular permeability and 13C urea 
washout [22].   
 At the other end of the cancer spectrum, pancreatic cancer has >90% 
mortality within 5 years of diagnosis, with early detection and surgery currently 
offering the only chance of survival [21].   In genetically engineered mouse models 
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[23,24] of pancreatic ductal adenocarcinoma the [1-13C]alanine/[1-13C]lactate ratio, 
following injection of  hyperpolarized [1-13C]pyruvate, was shown to decrease with 
disease progression [13]. Similarly, hepatocellular carcinoma has a mortality rate in 
excess of 95%, making it the second most common cause of cancer-mortality 
worldwide. However, localized tumors suitable for resection or ablation have a good 
prognosis [25]. Differentiation of small malignant tumors from benign tumors and 
cirrhotic liver is challenging but may be aided by metabolic imaging. In hepatoma 
cells glutamine uptake is 10-30 fold greater than in normal hepatocytes [26-28]. 
Following injection of hyperpolarized [5-13C]glutamine, [5-13C]glutamate could be 
detected in vivo in rat hepatomas but not in normal liver [29,30]. However, [5-
13C]glutamine does not polarize well and has a short T1, and although there are 
techniques that can improve these characteristics slightly [31], they may ultimately 
limit clinical translation.  
 While it is unrealistic to suggest population-based screening with any cross-
sectional imaging technique, let alone hyperpolarized MRI, it may be feasible for 
highly stratified groups, such as patients with hereditary cancer syndromes. The 
development of more sensitive and specific circulating biomarkers could also 
facilitate patient stratification prior to confirmation with imaging.  
 
Tumor phenotyping 
 
Isocitrate dehydrogenase (IDH) 
 Wild-type IDH catalyzes oxidative decarboxylation of isocitrate to α-
ketoglutarate (α-KG). The most common mutation of IDH in cancer leads to a 
neomorphic function and the reduction of α-KG to D-2-hydroxyglutarate (2-HG), a 
metabolite present in very low concentrations in normal tissue and which has been 
termed an oncometabolite because of its effects on epigenetic modifications and 
gene expression [4]. IDH1 (the cytosolic isoform) is mutated in >70% of low-grade 
gliomas and non-invasive determination of IDH1 mutational status would change the 
approach to surgical resection [32]. Hyperpolarized [2-13C]pyruvate allows 
visualization of TCA cycle metabolites and in IDH1 mutated cells there was reduced 
[5-13C]glutamate labeling because of down-regulation of pyruvate dehydrogenase 
activity [33,34]. [1-13C]2-HG has been observed in tumor models in vivo following 
injection of hyperpolarized [1-13C]α-KG [35] and [1-13C]glutamine [36]. 
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ɣ-glutamyl-transpeptidase (GGT) 
 GGT is bound to the outer aspect of the plasma membrane, where it 
catalyzes degradation of extracellular glutathione to its constituent amino acids 
(glutamate, cysteine and glycine), which can then be used for intracellular 
glutathione synthesis. GGT is over-expressed in a variety of tumors where it may 
have a role in progression, invasion and drug resistance [37]. Cleavage of 
hyperpolarized ɣ-glutamyl-[1-13C]glycine to [1-13C]glycine, catalyzed by GGT, was 
measured in normal rat organs [38]. The next step will be to determine whether 
tumor over-expression of GGT can be detected.  
 
Early Detection of Treatment Response 
  
 Early detection of treatment response could reduce the duration of ineffective 
therapies, decreasing costs and unnecessary side effects and facilitating an earlier 
switch to alternative treatments. Interim 18FDG-PET-CT scans after one or two 
cycles of chemotherapy is now standard of care for most lymphomas [39-41]. There 
is also emerging evidence that early response can be detected with 18FDG-PET in 
melanoma patients treated with the BRAF inhibitor vemurafenib or immune 
checkpoint inhibitors targeting CTLA-4 or PD1 [42-45]. However, overall there has 
been a reluctance to utilize 18FDG-PET for this purpose, with some studies reporting 
lack of efficacy and because of exaggerated fears over repeated ionizing radiation 
exposure [46] and the poorly understood metabolic “flare effect” [47-49]. 
 Hyperpolarized substrates avoid the use of ionizing radiation and, by using 
probes more specific than 18FDG for cancer metabolism or the chemotherapeutic 
being used, may be more sensitive to early therapy induced changes in metabolism. 
So far [1-13C]pyruvate has been the most thoroughly investigated hyperpolarized 
substrate for treatment response monitoring. Chemotherapy and radiotherapy have 
been observed to alter hyperpolarized [1-13C]pyruvate metabolism in numerous 
animal models, usually leading to a decrease in lactate labelling[11,50-56].  
Detection of treatment response in a prostate cancer patient was reported recently. 
Following six weeks of androgen deprivation therapy [1-13C]lactate was virtually 
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undetectable. With 1H-MRI, there were only small changes in the apparent diffusion 
coefficient of tissue water and tumor size [10].  
 However, a number of studies have failed to detect treatment response with 
[1-13C]pyruvate or shown that it is less sensitive than tumor size measurements [57-
59]. In these instances a different approach to response detection is required. 
Following injection of hyperpolarized [1,4 13C2]fumarate the detection of malate is a 
sensitive indicator of cell death [59,60]. Hydration of hyperpolarized [1,4 
13C2]fumarate to malate, catalysed by fumarase, is seen in areas of necrosis, where 
increases in cell membrane permeability improve cell uptake of fumarate and result 
in leakage of fumarase into the extracellular space [60]. 
  
Tumor Microenvironment 
 
pH 
 The acidic extracellular environment of tumors, which is often associated with 
tumor hypoxia, contributes to the malignant phenotype by upregulating signaling 
pathways promoting tumor growth, inflammation, angiogenesis and metastasis, 
whilst inhibiting immune cell activation, chemotherapeutic delivery to the tumor and 
radio-sensitivity [61]. 
 Injection of hyperpolarized 13C-bicarbonate results in the production of 13CO2 
and the extracellular pH and carbonic anhydrase activity can be determined from the 
H13CO3–/13CO2 signal ratio [62,63]. Several hyperpolarized probes that exhibit pH-
dependent chemical shifts have also been described. 15N2-imidazole and several 
15N-pyridine derivatives have been hyperpolarized and tested in vitro with chemical 
shifts of up to 60 ppm per pH unit [64,65]. More recently [1,5-13C]zymonic acid has 
been used in vivo to image the pH of multiple tissues [66]. 
 
Redox Status 
 Tumors generally have elevated production of reactive oxygen species (ROS), 
which promote tumor development and resistance to therapy [67]. To regulate 
increased ROS production, antioxidant production is also increased and several 
hyperpolarized probes have been used to probe these regulatory mechanisms. [1-
13C]alanine has been used to measure lactate/pyruvate ratio as a surrogate for the 
NAD+/NADH ratio [68]. The pentose phosphate pathway (PPP) produces NADPH, 
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required by glutathione reductase to maintain levels of reduced glutathione, a key 
anti-oxidant. Flux through the PPP has been estimated in tumors by measuring [U-
2H, U-13C]glucose conversion to 6-phosphogluconate, a PPP intermediate [69,70] 
and recently the production of H13CO3- was detected in mouse liver following 
injection of δ-[1-13C]gluconolactone [71].  Ascorbic acid (AA) combats oxidative 
stress by reducing ROS and in the process producing dehydroascorbic acid (DHA). 
DHA can then be reduced back to AA via glutathione or NADPH dependent 
reactions. Hyperpolarized [1-13C]dehydroascorbic acid and measurement of its 
reduction to [1-13C]ascorbic acid has been used to probe intracellular redox status in 
a number of animal models of cancer [72-74]. 
       
Technical Developments 
 
 The transient nature of hyperpolarization limits it use to metabolic events 
occurring on a timescale of seconds to minutes. Furthermore, each excitation 
required to produce a spectrum or image results in further depletion of the 
hyperpolarization. 3D imaging sequences have been described recently that have 
improved the nominal spatial resolutions in lactate and pyruvate images to ≤0.003 
cm3, with image acquisition times of <2 s [75,76].  Improved polarizers and injection 
protocols could improve the signal available initially [16,77] and rapid removal of the 
radical, which dramatically prolongs polarization lifetime, has been achieved using a 
number of different methods [78,79]. Provided the sample remains at low 
temperature and in a relatively high magnetic field T1s > 20 h are possible [78]. This 
would permit centralized substrate hyperpolarization followed by transport to multiple 
locations for clinical use, in a similar fashion to 18F-labeled PET tracers, dispensing 
with the requirement to have a hyperpolarizer in close proximity to the MRI scanner.  
 Transferring polarization from hyperpolarized 13C nuclei to spin-coupled 1H 
nuclei can be used to further enhance signal detection. Dynamic 1H imaging of 
lactate methyl protons following injection of [1-13C]pyruvate was recently 
demonstrated in vivo [80]. The resulting signal enhancements are likely to be greater 
at the lower magnetic field strengths used in the clinic. 
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PET-MRI 
 PET-MRI combines improved soft tissue contrast with the functional 
information provided by both PET and MRI and is likely to be of particular use where 
MRI is already the anatomical imaging technique of choice e.g. in brain, liver and 
prostate [81]. Simultaneous hyperpolarized 13C MRI and PET studies permit more 
extensive metabolic phenotyping of tumors, as already demonstrated in pre-clinical 
studies (Figure 2) [82-85]. 18FDG can be used to measure the first two steps of 
glycolysis, cell uptake via the glucose transporters and irreversible trapping after 
phosphorylation by hexokinase. Therefore the combination of 18FDG and [1-
13C]pyruvate may yield a single metric that estimates glucose uptake and its 
subsequent metabolism. For example, high 18FDG uptake and low [1-13C]lactate 
production may suggest that mitochondrial oxidation of glucose predominates, 
whereas high 18FDG uptake and high [1-13C]lactate labeling would be indicative of 
the Warburg effect. Studies so far have either demonstrated concordance between 
18FDG uptake and [1-13C]lactate production [83,85] or that hyperpolarized tracers 
can have improved tumor specificity when compared to 18FDG [82,84]. 
 
Conclusions 
 For a field still very much in its infancy a remarkable number of substrates 
have been hyperpolarized and have provided novel, pre-clinical insights into tumor 
metabolism in vivo. Hyperpolarized [1-13C]pyruvate has already entered clinical trials 
and other substrates will undoubtedly follow. The major weakness is the transient 
nature of the signal, limiting studies to fast metabolic reactions in pre-defined body 
regions. Therefore it is very unlikely that hyperpolarized substrates will replace 
nuclear medicine techniques for staging metastatic cancers. However, its great 
strength is the potential for kinetic measurements of multiple enzymatic processes 
providing functional data. For use as a clinical biomarker, these data must be 
sufficiently sensitive and specific to inform treatment decisions, prognosis, or monitor 
treatment response in ways that are not possible by using circulating biomarkers or 
other imaging modalities. If that proves to be the case then routine functional 
precision imaging using this technique could become a clinical reality.  
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Metabolite T1 (s) Polarization Measurable products Measures References 
[1-13C]pyruvate 40 (9.4 
T) 
>60% [1-13C]lactate, 13C 
bicarbonate, 1-
13C]alanine 
MCT expression, LDH, PDH 
and ALT activity, NADH 
availability 
[11,77] 
[1,4-13C2]fumarate 24 (9.4 
T) 
26 – 35% [1,4-13C2]malate Necrosis – leakage of 
fumarase from necrotic cells 
increases conversion of  [1,4-
13C2]fumarate to [1,4-
13C2]malate 
[60] 
[1-13C]lactate 45 (3 
T) 
7% [1-13C]pyruvate, [1-
13C]alanine, 13C-
bicarbonate 
MCT expression, LDH, PDH 
and ALT activity, NAD+ 
availability 
[86] 
[1-13C]alanine 66 (3 
T) 
25 [1-13C]pyruvate, [1-
13C]lactate 
NADH availability, LDH and 
ALT expression 
[68] 
[1-13C]α-
ketoglutarate 
52 (3 
T) 
16.3 ± 3% [1-13C]2-
hydroxyglutarate 
Mutant IDH expression, 
NADPH availability 
[35] 
[1-13C]glutamine 31 (1 
T) 
34.7 ±7% [1-13C]2-
hydroxyglutarate 
Mutant IDH expression [36] 
[5-13C]glutamine 16 (9.4 
T) 
5% [5-13C]glutamate Glutaminase activity, 
glutamine transport 
[29] 
[1-13C]glutamate 34 (9.4 
T) 
28% [1-13C]α-ketoglutarate ALT activity, pyruvate 
availability, glutamate transport 
[87] 
[U-2H, U-13C]glucose 9 (7 T) 15% [1-13C]lactate, [1-13C]6-
phosphogluconate, [2-
Glycolysis [70] 
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13C]dihydroxyacetone 
phosphate, 13C-
bicarbonate 
 
ɣ-glutamyl-[1-
13C]glycine 
30 (9.4 
T) 
5.4% [1-13C]glycine GGT activity [38] 
[1-13C]acetate 16.2 
(9.4 T) 
13% [1-13C]acetylCoA, [1-
13C]acetylcarnitine 
MCT expression, acetylCoA 
synthetase and carnitine 
acetyltransferase activity 
[88] 
 Table 1. The properties of some hyperpolarized subtrates that have been used in cancer studies. The T1 is the spin lattice 
relaxation time and is a measure of the polarization lifetime. The numbers in parentheses are the field strengths at which these 
relaxation times were measured.  Abbreviations: MCT, monocarboxylate transporter; LDH, lactate dehydrogenase; PDH, pyruvate 
dehydrogenase; ALT, alanine transaminase; IDH, isocitrate dehydrogenase; GGT, ɣ-glutamyltransferase.  
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Figure legends 
 
Figure 1. Metabolic processes targeted with hyperpolarized 13C-labeled 
metabolites. Color coding: pink – enzymes; yellow – hyperpolarized 13C-labeled 
substrates; green – measurable hyperpolarized 13C-labeled products; cyan – 
hyperpolarized 13C-labeled substrates and measurable products (depending on the 
substrate injected). Abbreviations: ALT – alanine transaminase; ASCTs – alanine, 
serine, cysteine transporters (there are also several other transporters that can 
transport glutamine into cells); BCAT – branched chain amino acid aminotransferase; 
CAIX – carbonic anhydrase 9; DCTs – dicarboxylate transporters; DHAR – 
dihydroascorbate reductase; GGT - ɣ-glutamyltransferase; GLDH – glutamate 
dehydrogenase; GLS – glutaminase; GLUTs – glucose transporters; GR – 
glutathione reductase; GSH – glutathione; GSSR – glutathione disulfide; IDH – 
isocitrate dehydrogenase; LDH – lactate dehydrogenase; MCTs – monocarboxylate 
transporters; PC – pyruvate carboxylase; PDH – pyruvate dehydrogenase; PPP – 
pentose phosphate pathway; SVCTs – sodium-ascorbate co-transporters. 
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Figure 2. Combined 18FDG-PET/CT and hyperpolarized [1-13C]pyruvate MRI. (a-
c) 3D CT bone reconstructions of a representative Colo205 tumor-bearing mouse 
with co-registered overlays of (a) 18FDG, (b) [1-13C]pyruvate and (c) [1-13C]lactate. (d 
– g) images from a single 2.5 mm thick axial slice. (d) T2-weighted fast spin echo 
image with overlaid with (e) 18FDG, (f) [1-13C]pyruvate and (g) [1-13C]lactate images. 
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